New drug OM336 aims to tame overactive immune system
NCT ID NCT07083960
First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times
Summary
This early-phase trial tests a new drug called OM336 in 32 adults with autoimmune cytopenias, conditions where the immune system attacks blood cells. The study focuses on safety and how the drug moves through the body, not yet on curing the disease. Participants must have tried at least one prior treatment without success.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AIHA - COLD AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Icon Cancer Center South Brisbane
RECRUITINGBrisbane, Queensland, 4066, Australia
-
Liverpool Hospital
RECRUITINGSydney, New South Wales, 2107, Australia
-
The Canberra Hospital
RECRUITINGCanberra, Australian Capital Territory, 2605, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug calm the immune System's attack on blood cells?
- Double attack on blood disorder: could two drugs beat one for stubborn ITP?
- Could a cholesterol drug and antioxidant help treat a rare bleeding disorder?
- New combo therapy aims to boost platelets in ITP patients
- New hope for lupus patients with dangerous low platelet counts
- New shot aims to boost platelets in bleeding disorder